John H. Trotter Multiple Sclerosis Center and Department of Neurology, Washington University, Campus Box 8111, 660 S Euclid Ave, St Louis, MO, 63110, USA,
Curr Neurol Neurosci Rep. 2013 Nov;13(11):390. doi: 10.1007/s11910-013-0390-z.
Multiple sclerosis (MS), a demyelinating disease of the central nervous system, was untreatable until the mid-1990s when beta-interferons and glatiramer acetate were introduced. These agents, while effective, were relatively nonspecific in action. Over the last 10 years, research has focused toward developing more targeted therapies for the disease. Monoclonal antibodies (mAbs) have been central to these efforts and many of the mAbs studied in MS have been singularly effective. We review here the 6 monoclonal antibodies that have been approved for MS or are in late-stage clinical trials, focusing on the drugs' efficacy and safety. Additionally, we review several monoclonal antibodies that were studied in MS but were found to be ineffective or even deleterious in this patient population.
多发性硬化症（MS）是一种中枢神经系统脱髓鞘疾病，直到 20 世纪 90 年代中期，β干扰素和醋酸格拉替雷问世后才得到治疗。这些药物虽然有效，但作用相对不特异。在过去的 10 年中，研究的重点是为该疾病开发更具针对性的治疗方法。单克隆抗体（mAbs）一直是这些努力的核心，许多在 MS 中研究的 mAbs 都非常有效。我们在此回顾了已批准用于 MS 或处于后期临床试验阶段的 6 种单克隆抗体，重点介绍了这些药物的疗效和安全性。此外，我们还回顾了一些在 MS 中进行研究但在该患者群体中被发现无效甚至有害的单克隆抗体。
